Department of Global Health, University of Washington, Seattle, Washington, United States of America.
PLoS One. 2012;7(1):e29777. doi: 10.1371/journal.pone.0029777. Epub 2012 Jan 11.
The incidence and correlates of breast milk HIV-1 RNA detection were determined in intensively sampled women receiving highly active antiretroviral therapy (HAART) for the prevention of mother-to-child HIV-1 transmission.
Women initiated HAART at 34 weeks of pregnancy. Breast milk was collected every 2-5 days during 1 month postpartum for measurements of cell-associated HIV DNA and cell-free HIV RNA. Plasma and breast milk were also collected at 2 weeks, 1, 3 and 6 months for concurrent HIV-1 RNA and DNA measurements. Regression was used to identify cofactors for breast milk HIV-1 RNA detection.
Of 259 breast milk specimens from 25 women receiving HAART, 34 had detectable HIV-1 RNA (13%, incidence 1.4 episodes/100 person-days 95% CI = 0.97-1.9). Fourteen of 25 (56%) women had detectable breast milk HIV-1 RNA [mean 2.5 log(10) copies/ml (range 2.0-3.9)] at least once. HIV-1 DNA was consistently detected in breast milk cells despite HAART, and increased slowly over time, at a rate of approximately 1 copy/10(6) cells per day (p = 0.02). Baseline CD4, plasma viral load, HAART duration, and frequency of breast problems were similar in women with and without detectable breast milk HIV-1 RNA. Women with detectable breast milk HIV-1 RNA were more likely to be primiparous than women without (36% vs 0%, p = 0.05). Plasma HIV-1 RNA detection (OR = 9.0, 95%CI = 1.8-44) and plasma HIV-1 RNA levels (OR = 12, 95% CI = 2.5-56) were strongly associated with concurrent detection of breast milk HIV-1 RNA. However, no association was found between breast milk HIV-1 DNA level and concurrent breast milk HIV-1 RNA detection (OR = 0.96, 95%CI = 0.54-1.7).
The majority of women on HAART had episodic detection of breast milk HIV-1 RNA. Breast milk HIV-1 RNA detection was associated with systemic viral burden rather than breast milk HIV-1 DNA.
在接受高效抗逆转录病毒治疗(HAART)以预防母婴 HIV-1 传播的密集采样女性中,确定了母乳中 HIV-1 RNA 检测的发生率和相关性。
女性在妊娠 34 周时开始接受 HAART。在产后 1 个月内,每 2-5 天采集一次母乳,以测量细胞相关 HIV DNA 和无细胞 HIV RNA。在 2 周、1 个月、3 个月和 6 个月时还采集血浆和母乳,同时测量 HIV-1 RNA 和 DNA。回归用于确定母乳 HIV-1 RNA 检测的协变量。
在接受 HAART 的 25 名女性的 259 份母乳样本中,有 34 份(13%)检测到 HIV-1 RNA(发生率为 1.4 例/100 人日,95%CI=0.97-1.9)。25 名女性中有 14 名(56%)至少有一次检测到母乳 HIV-1 RNA[平均 2.5 log(10)拷贝/ml(范围 2.0-3.9)]。尽管接受了 HAART,但仍能在母乳细胞中持续检测到 HIV-1 DNA,且随着时间的推移缓慢增加,每天约增加 1 个拷贝/10(6)细胞(p=0.02)。在有和没有可检测到的母乳 HIV-1 RNA 的女性中,基线 CD4、血浆病毒载量、HAART 持续时间和乳房问题的频率相似。可检测到母乳 HIV-1 RNA 的女性更可能是初产妇,而不是经产妇(36% vs 0%,p=0.05)。血浆 HIV-1 RNA 检测(OR=9.0,95%CI=1.8-44)和血浆 HIV-1 RNA 水平(OR=12,95%CI=2.5-56)与同时检测母乳 HIV-1 RNA 密切相关。然而,母乳 HIV-1 DNA 水平与同时检测母乳 HIV-1 RNA 之间没有关联(OR=0.96,95%CI=0.54-1.7)。
大多数接受 HAART 的女性均出现母乳 HIV-1 RNA 间歇性检测。母乳 HIV-1 RNA 检测与全身病毒载量有关,而与母乳 HIV-1 DNA 无关。